In summary, the data presented in this work provide evidence of a role for cPLA2α in breast cancer progression; cPLA2α expression correlated with clinicopathological parameters of poor prognosis and with highly aggressive tumours characterised by low ER expression, high EGFR expression and basal phenotype. The gene discussed is EGFR; the disease is breast carcinoma.